QTTB Q32 Bio Inc. - Common Stock
$15,44
Cena · Sie 19, 2026
Dane fundamentalne na dzień Sie 5, 2026
Zakres 52 tyg.
$2–$24
63% of range
Ocena Analityków
BUY
11 analysts
Cena Docelowa
$43
+177% upside
P/E (TTM)
6.4
ROE
200.3%
Marża Zysku Netto
55.5%
QTTB Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$15.44
Kapitalizacja Rynkowa
$198M
P/E (TTM)
6.4
EPS (TTM)
$2.42
Przychody (TTM)
$54M
Stopa dywidendy
—
ROE
200.3%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$2 – $24
QTTB Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$54M
2018-12-31
→
2025-12-31
EPS
$2.42
2021-12-31
→
2025-12-31
Wolny przepływ pieniężny
$-34M
2018-12-31
→
2025-12-31
Marże
55.5%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
QTTB
Mediana porównawcza
P/E (TTM)
6.4
16.6
P/S (TTM)
3.7
9.4
P/B
4.7
2.4
Price / FCF (Cena / FCF)
-5.9
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
QTTB
Mediana porównawcza
Operating Margin (Marża Operacyjna)
31.4%
—
Net Profit Margin (Marża Zysku Netto)
55.5%
-298.0%
ROA
38.7%
-38.4%
ROE
200.3%
-63.7%
ROIC
40.2%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
QTTB
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
4.9
3.9
Quick Ratio (Wskaźnik Szybkości)
4.3
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
QTTB
Mediana porównawcza
Revenue CAGR 3Y (Przychody CAGR 3L)
155.9%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
81.8%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
QTTB
Mediana porównawcza
QTTB Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
11 analityków
- Mocne kupno 3 27,3%
- Kup 7 63,6%
- Trzymaj 1 9,1%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
4 analityków · 2026-08-18
Mediana
$38.00
Średnia
$42.75
← Poniżej wszystkich celów
$15.44
Niski
$36.00
Wysoki
$59.00
Średni cel
$38.00
+146,2%
Średnia cel
$42.75
+177,0%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
1.00%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $-0.44 | $-0.55 | 0.11% |
| 31 marca 2026 | $-0.54 | $-0.69 | 0.15% |
| 31 grudnia 2025 | $3.65 | $-0.88 | 4.5% |
| 30 września 2025 | $-0.60 | $-1.21 | 0.61% |
| 30 czerwca 2025 | $-0.78 | $-1.00 | 0.22% |
| 31 marca 2025 | $-0.90 | $-1.25 | 0.35% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| QTTB | $43M | 1.4 | — | 55.5% | 200.3% | — |
| ZURA | — | — | — | — | — | — |
| EVMN | $540M | -1.5 | 85.7% | -529.8% | -401.2% | — |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | — |
| MPLT | $773M | -0.9 | — | — | -151.1% | — |
| CABA | $220M | -1.0 | — | — | -115.5% | — |
| OCGN | $422M | -5.6 | 8.8% | -1537.4% | 1488.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| R&D Expense | $19M | $48M | $32M | $98M | $93M | $100M | $89M | $48M | |
| SG&A Expense | $18M | $18M | $10M | $38M | $37M | $33M | $22M | $17M | |
| Operating Expenses | $37M | $66M | $42M | $136M | $130M | $133M | $112M | $65M | |
| Operating Income | $17M | $-66M | $-48M | $-133M | $-96M | $-130M | $-110M | $-60M | |
| Other Non-op | $1M | $4M | $1M | $134M | $185.0K | $2M | $6M | $4M | |
| Pretax Income | $30M | $-46M | $-53M | $1M | $-96M | · | · | · | |
| Income Tax | $0 | $21.0K | $318.0K | $715.0K | $0 | $0 | $0 | $0 | |
| Net Income | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| EPS (Basic) | $2.42 | $-5.12 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| EPS (Diluted) | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| Shares (Basic) | 12,300,568 | 9,320,884 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| Shares (Diluted) | 12,314,796 | 9,657,696 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| EBITDA | $17M | $-66M | · | $-133M | $-96M | $-130M | $-110M | $-62M |
Bilans 23
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $78M | $26M | $34M | $108M | $217M | $54M | $38M | |
| Short-term Investments | · | $0 | $0 | $141M | · | · | · | · | |
| Prepaid Expense | $7M | $4M | $3M | $6M | $7M | $2M | $4M | $7M | |
| Other Current Assets | $20.0K | $396.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $55M | $82M | $29M | $181M | $192M | $220M | $267M | $222M | |
| PP&E (Net) | $979.0K | $1M | $2M | $1M | $2M | $37M | $43M | $36M | |
| PP&E (Gross) | $3M | $3M | $3M | $7M | $8M | $53M | $51M | $38M | |
| Accum. Depreciation | $2M | $1M | $966.0K | $6M | $6M | $16M | $8M | $2M | |
| Other Non-current Assets | $0 | $116.0K | $5M | · | · | · | · | · | |
| Total Assets | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Accounts Payable | $879.0K | $3M | $3M | $1M | $2M | $5M | $3M | $16M | |
| Accrued Liabilities | $4M | $7M | $10M | · | · | · | · | · | |
| Current Liabilities | $11M | $16M | $14M | $23M | $17M | $23M | $12M | $23M | |
| Capital Leases | $5M | $6M | $6M | $28M | $24M | $13M | · | · | |
| Other Non-current Liabilities | $0 | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $20M | $87M | $119M | $50M | $42M | $68M | $52M | $63M | |
| Common Stock | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $5.0K | $4.0K | $3.0K | |
| Paid-in Capital | $247M | $240M | $4M | $608M | · | · | · | · | |
| Retained Earnings | $-205M | $-235M | $-187M | $-429M | $-424M | $-328M | $-200M | $-96M | |
| AOCI | · | $0 | $0 | $-404.0K | $-7.0K | $0 | $183.0K | $-77.0K | |
| Stockholders' Equity | $42M | $6M | $-183M | $-131M | $170M | $196M | $259M | $196M | |
| Liabilities + Equity | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Shares Outstanding | 12,858,047 | 12,197,615 | 359,569 | 57,483,910 | 57,150,274 | 50,265,575 | 45,116,742 | 37,358,526 |
Przepływy pieniężne 11
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $5M | $4M | $1M | $13M | $17M | $13M | $8M | $3M | |
| Deferred Tax | · | $100.0K | $300.0K | · | · | · | · | · | |
| Restructuring | · | · | $10M | · | · | · | · | · | |
| Operating Cash Flow | $-34M | $-68M | $-19M | $-114M | $-110M | $-94M | $-91M | $-43M | |
| CapEx | $0 | $75.0K | $5.0K | $1M | $2M | $4M | $22M | $25M | |
| Investing Cash Flow | $7M | $20M | $-5.0K | $37M | $-51M | $205M | $-52M | $-122M | |
| Stock Issued | $0 | $42M | $0 | $0 | $50M | · | $135M | · | |
| Net Stock Activity | $0 | $42M | · | $0 | $50M | · | $135M | · | |
| Financing Cash Flow | $-3M | $95M | $406.0K | $596.0K | $52M | $53M | $158M | $151M | |
| Net Change in Cash | · | · | $5M | $-76M | $-108M | $164M | $15M | $-13M | |
| Free Cash Flow | $-34M | $-68M | · | $-115M | $-112M | $-98M | $-113M | $-68M |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| Net Margin | 55.5% | · | · | -156.0% | -281.9% | -4762.9% | -6237.4% | -1553.1% | |
| Pretax Margin | 55.5% | · | · | 37.3% | · | · | · | · | |
| EBITDA Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| ROA | 38.7% | -68.5% | · | -2.3% | -40.3% | -44.8% | -36.5% | -28.8% | |
| ROE | 200.3% | -398.3% | · | -2.6% | -52.0% | -70.3% | -40.2% | -28.0% | |
| ROIC | 40.2% | -1165.3% | · | -30.2% | · | · | · | · |
Płynność i wypłacalność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.0 | · | 8.0 | 11.1 | 9.7 | 21.5 | 8.7 | |
| Quick Ratio | 4.3 | 4.7 | · | 1.5 | 6.3 | 9.6 | 4.3 | 1.5 |
Efektywność 1
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.0 | · | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -90.6% | 1157.2% | · | · | · | |
| Revenue CAGR 3Y | 155.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 81.8% | · | · | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| Net Income TTM | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| Market Cap | $43M | $42M | · | $1.30B | $3.74B | $10.21B | $16.81B | $15.04B | |
| P/E | 1.4 | -0.5 | -0.1 | -252.0 | -37.9 | · | · | · | |
| P/S | 0.8 | · | · | 406.4 | 110.2 | 3780.5 | 10090.3 | 2825.3 | |
| P/B | 1.0 | 7.4 | · | 7.3 | 22.1 | 52.1 | 65.0 | 77.2 | |
| P / Tangible Book | 1.0 | 7.4 | · | · | 22.1 | 52.1 | · | · | |
| P / Cash Flow | -1.3 | -0.6 | · | -11.5 | -34.1 | -108.3 | -184.0 | -353.3 | |
| P / FCF | -1.3 | -0.6 | · | -11.3 | -33.4 | -104.2 | -148.5 | -222.8 | |
| Earnings Yield | 72.9% | -191.3% | -1406.8% | -0.40% | -2.6% | · | · | · |
Rachunek zysków i strat 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-15M | $2M | $3M | $3M | $802.0K | $802.0K | |
| R&D Expense | $4M | $3M | $3M | $4M | $5M | $7M | $11M | $14M | $13M | $10M | $8M | $7M | $8M | $8M | $27M | $26M | |
| SG&A Expense | $5M | $5M | $5M | $4M | $4M | $5M | $4M | $4M | $5M | $5M | $3M | $2M | $2M | $2M | $8M | $8M | |
| Operating Expenses | $9M | $8M | $8M | $8M | $9M | $12M | $15M | $19M | $18M | $15M | $11M | $10M | $10M | $10M | $35M | $34M | |
| Operating Income | $-9M | $-8M | $46M | $-8M | $-9M | $-12M | $-15M | $-19M | $-18M | $-15M | $-26M | $-8M | $-7M | $-7M | $-34M | $-33M | |
| Other Non-op | $319.0K | $113.0K | $115.0K | $188.0K | $-318.0K | $1M | $358.0K | $1M | $2M | $158.0K | $196.0K | $84.0K | $165.0K | $578.0K | $1M | $1M | |
| Pretax Income | · | · | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-16M | $1M | $-27M | $-14M | $-6M | $-7M | $-33M | $-32M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $21.0K | $0 | $0 | $0 | $383.0K | $-65.0K | $0 | $0 | $-403.0K | $46.0K | |
| Net Income | $-9M | $-8M | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-17M | $1M | $-27M | $-14M | $-6M | $-7M | $-34M | $-34M | |
| EPS (Basic) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $-3.27 | $-1.46 | $-1.42 | $1.03 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.60 | $-0.59 | |
| EPS (Diluted) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $2.63 | $-1.46 | $-1.42 | $-6.33 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.58 | $-0.59 | |
| Shares (Basic) | 20,342,345 | 14,095,371 | -24,335,204 | 12,240,542 | 12,197,615 | 12,197,615 | -15,715,032 | 12,076,412 | 11,964,224 | 995,280 | -689,787 | 346,288 | 347,936 | 344,623 | -114,712,971 | 57,447,192 | |
| Shares (Diluted) | 20,342,345 | 14,095,371 | -24,320,976 | 12,240,542 | 12,197,615 | 12,197,615 | -16,717,120 | 12,076,412 | 11,964,224 | 2,334,180 | -689,787 | 346,288 | 347,936 | 344,623 | -115,308,584 | 57,447,192 | |
| EBITDA | $-9M | $-8M | · | $-8M | $-9M | $-12M | · | $-19M | $-18M | $-15M | · | $-31M | $-31M | $-28M | · | $-33M |
Bilans 23
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106M | $51M | $48M | $49M | $55M | $65M | $78M | $89M | $98M | $116M | $26M | $29M | $77M | $39M | $34M | $43M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | · | · | $0 | $74M | $50M | $111M | · | · | |
| Prepaid Expense | $3M | $6M | $7M | $2M | $3M | $3M | $4M | $5M | $4M | $3M | $3M | $3M | $4M | $4M | $6M | $12M | |
| Other Current Assets | $19.0K | $20.0K | $20.0K | $24.0K | $77.0K | $93.0K | $396.0K | $229.0K | $51.0K | $67.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $110M | $57M | $55M | $51M | $58M | $69M | $82M | $94M | $112M | $138M | $29M | $107M | $131M | $154M | $181M | $213M | |
| PP&E (Net) | $804.0K | $889.0K | $979.0K | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $0 | $845.0K | $1M | $1M | $1M | |
| PP&E (Gross) | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $0 | $7M | $7M | $7M | $8M | |
| Accum. Depreciation | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $966.0K | $0 | $7M | $6M | $6M | $7M | |
| Other Non-current Assets | · | · | $0 | $0 | $570.0K | $444.0K | $116.0K | $40.0K | $1M | $1M | $5M | · | · | · | · | · | |
| Total Assets | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Accounts Payable | $2M | $653.0K | $879.0K | $973.0K | $910.0K | $3M | $3M | $1M | $2M | $5M | $3M | $8M | $3M | $4M | $1M | $5M | |
| Accrued Liabilities | $4M | $4M | $4M | $4M | $4M | $5M | $7M | $9M | $11M | $20M | $10M | · | · | · | · | · | |
| Current Liabilities | $5M | $11M | $11M | $11M | $12M | $15M | $16M | $14M | $17M | $33M | $14M | $25M | $23M | $19M | $23M | $25M | |
| Capital Leases | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $27M | $27M | $27M | $28M | $28M | |
| Other Non-current Liabilities | · | · | $0 | $55M | $55M | $55M | $55M | $55M | $55M | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $10M | $17M | $20M | $76M | $78M | $83M | $87M | $86M | $91M | $104M | $119M | $52M | $50M | $46M | $50M | $54M | |
| Common Stock | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Paid-in Capital | $327M | $259M | $247M | $244M | $243M | $242M | $240M | $239M | $237M | $235M | $4M | $614M | $612M | $610M | · | · | |
| Retained Earnings | $-222M | $-213M | $-205M | $-263M | $-255M | $-246M | $-235M | $-221M | $-203M | $-186M | $-187M | $-526M | $-493M | $-458M | $-429M | $-395M | |
| AOCI | · | · | · | $0 | $0 | $0 | · | $-1.0K | $-1.0K | $-5.0K | $0 | $-36.0K | $-88.0K | $-182.0K | $-404.0K | $-457.0K | |
| Stockholders' Equity | $106M | $46M | $42M | $-18M | $-12M | $-4M | $6M | $18M | $34M | $49M | $-183M | $88M | $119M | $152M | $178M | $209M | |
| Liabilities + Equity | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Shares Outstanding | 23,736,600 | 14,629,463 | 12,858,047 | 12,304,352 | 12,197,615 | 12,197,615 | 12,197,615 | 12,138,869 | 11,995,206 | 11,929,520 | 359,569 | 57,902,210 | 57,798,133 | 57,794,767 | 57,483,910 | 57,480,610 |
Przepływy pieniężne 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $417.0K | $521.0K | $-4M | $-2M | $296.0K | $3M | $3M | |
| Restructuring | · | · | · | $0 | $0 | $900.0K | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-3M | $-6M | $-6M | $-4M | $-11M | $-12M | $-11M | $-20M | $-22M | $-15M | $-11M | $42M | $2M | $-12M | $-27M | $-25M | |
| CapEx | · | · | $0 | $0 | · | · | $2.0K | $58.0K | $15.0K | $0 | $0 | $-223.0K | $-224.0K | $5.0K | $9.0K | $6.0K | |
| Investing Cash Flow | $0 | $0 | $7M | $0 | $0 | $0 | $-2.0K | $10M | $10M | $97.0K | $0 | $-92M | $-31M | $-5.0K | $18M | $-108M | |
| Stock Issued | $0 | $10M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $42M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | $10M | · | · | · | $0 | · | · | · | $42M | · | · | · | · | · | · | |
| Financing Cash Flow | $59M | $9M | $-2M | $-2M | · | · | $317.0K | $997.0K | $-6M | $99M | $76.0K | $178.0K | $-120.0K | $15.0K | $32.0K | $124.0K | |
| Net Change in Cash | · | · | · | · | · | · | · | · | · | · | · | $-48M | $37M | $5M | $-9M | $-133M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-15M | · | · | · | $-26M | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| Net Margin | 3636.6% | 3963.0% | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -9899.4% | -3596.5% | · | -4205.2% | |
| Pretax Margin | · | · | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -8278.2% | -3247.1% | · | -3939.3% | |
| EBITDA Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| ROA | -9.8% | -10.7% | · | -9.1% | -10.0% | -9.5% | · | -14.4% | -11.6% | 0.59% | · | -16.4% | -15.4% | -11.3% | · | -13.7% | |
| ROE | -19.1% | -36.0% | · | 9658.8% | -89.2% | -49.3% | · | -33.0% | -22.2% | 1.0% | · | -22.2% | -19.5% | -13.8% | · | -16.6% | |
| ROIC | · | · | · | 41.1% | 75.0% | 304.6% | · | -102.8% | -53.5% | -30.4% | · | -35.1% | -25.8% | -18.1% | · | -15.7% |
Płynność i wypłacalność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.3 | 5.4 | · | 4.6 | 5.1 | 4.7 | · | 6.5 | 6.5 | 4.2 | · | 4.2 | 5.7 | 8.3 | · | 8.4 | |
| Quick Ratio | 19.7 | 4.8 | · | 4.4 | 4.8 | 4.5 | · | 6.2 | 5.7 | 3.5 | · | 4.1 | 5.5 | 8.1 | · | 1.7 |
Efektywność 1
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | -0.0 | -0.0 | · | -0.0 | -0.0 | -0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $2M | · | $2M | $2M | $2M | · | $2M | $5M | $8M | · | $9M | $8M | $5M | · | $4M | |
| Net Income TTM | $-33M | $-36M | · | $-46M | $-55M | $-45M | · | $-48M | $-36M | $-26M | · | $-60M | $-75M | $22M | · | $-1M | |
| Market Cap | $302M | $94M | · | $24M | $18M | $20M | · | $542M | $215M | $203M | · | $1.22B | $921M | $1.07B | · | $1.67B | |
| P/E | -5.4 | -2.3 | · | -0.5 | -0.3 | -0.2 | · | -0.9 | -0.3 | -0.2 | · | -0.3 | -0.4 | -1.0 | · | -579.6 | |
| P/S | 162.7 | 50.5 | · | 13.1 | 9.8 | 10.8 | · | 291.4 | 42.5 | 25.4 | · | 138.4 | 118.7 | 200.2 | · | 408.0 | |
| P/B | 2.9 | 2.0 | · | -1.3 | -1.5 | -5.0 | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Tangible Book | 2.9 | 2.0 | · | · | · | · | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Cash Flow | · | -14.8 | · | · | · | -1.6 | · | · | · | -14.0 | · | · | · | -41.1 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -14.0 | · | · | · | -40.8 | · | · | |
| Earnings Yield | -18.5% | -43.9% | · | -188.9% | -306.0% | -612.7% | · | -111.5% | -361.9% | -489.3% | · | -368.7% | -236.2% | -104.4% | · | -0.17% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $54M | $0 | $-7M | $3M | $34M |
| Marża Operacyjna % | 31.4% | — | — | -4154.6% | -282.4% |
| Zysk netto | $30M | $-48M | $-54M | $-5M | $-96M |
| Rozwodniony EPS | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 4.9 | 5.0 | — | 8.0 | 11.1 |
| Wskaźnik Szybkości | 4.3 | 4.7 | — | 1.5 | 6.3 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-34M | $-68M | — | $-115M | $-112M |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 77 emitentów · $280.5M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 33 (+25 vs poprzedni kw.) | 8 (0 vs poprzedni kw.) | 14 (+1 vs poprzedni kw.) | 14 (+4 vs poprzedni kw.) | +13.3M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | $52 590 554 | 4 127 987 | 18,75% | Akcje |
| Boxer Capital Management, LLC | $40 122 209 | 3 149 310 | 14,30% | Akcje |
| Atlas Venture Life Science Advisors, LLC | $34 615 930 | 2 717 106 | 12,34% | Akcje |
| BVF INC/IL | $29 939 000 | 2 350 000 | 10,67% | Akcje |
| RA CAPITAL MANAGEMENT, L.P. | $29 715 502 | 2 332 457 | 10,59% | Akcje |
| Point72 Asset Management, L.P. | $14 949 065 | 1 173 396 | 5,33% | Akcje |
| Opaleye Management Inc. | $11 860 940 | 931 000 | 4,23% | Akcje |
| Logos Global Management LP | $10 192 000 | 800 000 | 3,63% | Akcje |
| SummitTX Capital, L.P. | $9 348 281 | 733 774 | 3,33% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $6 609 550 | 518 803 | 2,36% | Akcje |
| Ikarian Capital, LLC | $5 478 200 | 430 000 | 1,95% | Akcje |
| Woodline Partners LP | $3 646 341 | 286 212 | 1,30% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $3 474 860 | 272 752 | 1,24% | Akcje |
| Sanofi | $3 109 617 | 244 083 | 1,11% | Akcje |
| ACORN CAPITAL ADVISORS, LLC | $2 754 019 | 216 171 | 0,98% | Akcje |
| Ikarian Capital, LLC | $2 548 000 | 200 000 | 0,91% | Opcja sprzedaży |
| RENAISSANCE TECHNOLOGIES LLC | $2 288 104 | 179 600 | 0,82% | Akcje |
| JANE STREET GROUP, LLC | $1 686 164 | 132 352 | 0,60% | Akcje |
| MONIMUS CAPITAL MANAGEMENT, LP | $1 682 139 | 132 036 | 0,60% | Akcje |
| BOOTHBAY FUND MANAGEMENT, LLC | $1 661 640 | 130 427 | 0,59% | Akcje |
| CITADEL ADVISORS LLC | $1 537 247 | 120 663 | 0,55% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $1 273 455 | 99 923 | 0,45% | Akcje |
| MARSHALL WACE, LLP | $854 153 | 67 045 | 0,30% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $843 605 | 66 217 | 0,30% | Akcje |
| BOOTHBAY FUND MANAGEMENT, LLC | $780 962 | 61 300 | 0,28% | Opcja sprzedaży |
| Carlyle Group Inc. | $769 020 | 60 363 | 0,27% | Akcje |
| STATE STREET CORP | $665 206 | 52 214 | 0,24% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $631 675 | 49 582 | 0,23% | Akcje |
| Quadrature Capital Ltd | $463 685 | 36 396 | 0,17% | Akcje |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $440 970 | 34 613 | 0,16% | Akcje |
| DAFNA Capital Management LLC | $419 095 | 32 896 | 0,15% | Akcje |
| Knott David M Jr | $387 449 | 30 412 | 0,14% | Akcje |
| Affinity Asset Advisors, LLC | $353 879 | 27 777 | 0,13% | Akcje |
| Squarepoint Ops LLC | $303 085 | 23 790 | 0,11% | Akcje |
| NORTHERN TRUST CORP | $301 059 | 23 631 | 0,11% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $297 377 | 23 342 | 0,11% | Akcje |
| MANGROVE PARTNERS IM, LLC | $282 191 | 22 150 | 0,10% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $255 857 | 20 083 | 0,09% | Akcje |
| LPL Financial LLC | $231 486 | 18 170 | 0,08% | Akcje |
| UBS Group AG | $183 698 | 14 419 | 0,07% | Akcje |
| Balyasny Asset Management L.P. | $157 237 | 12 342 | 0,06% | Akcje |
| ExodusPoint Capital Management, LP | $144 421 | 11 336 | 0,05% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $139 223 | 10 928 | 0,05% | Akcje |
| XTX Topco Ltd | $138 535 | 10 874 | 0,05% | Akcje |
| Vanguard Global Advisers, LLC | $61 458 | 4 824 | 0,02% | Akcje |
| Nuveen Asset Management, LLC | $54 758 | 15 918 | 0,02% | Akcje |
| MORGAN STANLEY | $54 132 | 4 249 | 0,02% | Akcje |
| FMR LLC | $43 163 | 3 388 | 0,02% | Akcje |
| CITIGROUP INC | $36 793 | 2 888 | 0,01% | Akcje |
| BlackRock, Inc. | $25 047 | 1 966 | 0,01% | Akcje |
| Private Wealth Asset Management, LLC | $21 658 | 1 700 | 0,01% | Akcje |
| Arax Advisory Partners | $14 154 | 1 111 | 0,01% | Akcje |
| FEDERATED HERMES, INC. | $13 377 | 1 050 | 0,00% | Akcje |
| Rockefeller Capital Management L.P. | $7 351 | 577 | 0,00% | Akcje |
| JONES FINANCIAL COMPANIES LLLP | $6 585 | 500 | 0,00% | Akcje |
| VANGUARD GROUP INC | $6 358 | 1 915 | 0,00% | Akcje |
| Russell Investments Group, Ltd. | $5 784 | 454 | 0,00% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $3 860 | 303 | 0,00% | Akcje |
| EverSource Wealth Advisors, LLC | $3 058 | 240 | 0,00% | Akcje |
| ACADIAN ASSET MANAGEMENT LLC | $2 779 | 218 234 | 0,00% | Akcje |
| NISA INVESTMENT ADVISORS, LLC | $2 115 | 166 | 0,00% | Akcje |
| Truvestments Capital LLC | $2 064 | 162 | 0,00% | Akcje |
| OSAIC HOLDINGS, INC. | $1 579 | 124 | 0,00% | Akcje |
| Allworth Financial LP | $1 376 | 108 | 0,00% | Akcje |
| SBI Securities Co., Ltd. | $1 198 | 94 | 0,00% | Akcje |
| Clearstead Advisors, LLC | $854 | 67 | 0,00% | Akcje |
| Caitong International Asset Management Co., Ltd | $573 | 45 | 0,00% | Akcje |
| Federation des caisses Desjardins du Quebec | $484 | 38 | 0,00% | Akcje |
| GROUP ONE TRADING LLC | $433 | 34 | 0,00% | Akcje |
| CWM, LLC | $250 | 39 | 0,00% | Akcje |
| Cambridge Investment Research Advisors, Inc. | $230 | 18 081 | 0,00% | Akcje |
| HRT FINANCIAL LP | $203 | 15 949 | 0,00% | Akcje |
| HARBOUR INVESTMENTS, INC. | $140 | 11 | 0,00% | Akcje |
| MERCER GLOBAL ADVISORS INC /ADV | $25 | 2 | 0,00% | Akcje |
| AdvisorNet Financial, Inc | $25 | 2 | 0,00% | Akcje |
| DANSKE BANK A/S | $13 | 1 | 0,00% | Akcje |
| ROYAL BANK OF CANADA | $0 | 28 | 0,00% | Akcje |
Insiderzy spółki 29 insiderów · 13 dyrektorzy generalni · 18 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jodie Pope Morrison | CEO | 16 lipca 2026 A | 353 104 | 0 | 3 | $-141 391 |
| Albert Seymour | President and Chief Executive Officer | 6 września 2023 M | 150 874 | 0 | 0 | $0 |
| Lee Kalowski | CFO and President | 16 lipca 2026 A | 142 443 | 0 | 3 | $-57 038 |
| Paul Alloway | Former President and Chief Operating Officer of Homology Medicines, Inc. | 25 marca 2024 S | 2 596 | 0 | 0 | $0 |
| Timothy P Kelly | Chief Operating Officer | 24 lutego 2022 A | 2 224 | 0 | 0 | $0 |
| Siyamak Rasty | Chief Operating Officer | 9 lipca 2019 S | 222 707 | 0 | 0 | $0 |
| Shelia M. Violette | Chief Scientific Officer | 16 lipca 2026 A | 130 569 | 0 | 2 | $-18 078 |
| Jason Campagna | Chief Medical Officer | 24 lutego 2025 A | 37 500 | 0 | 0 | $0 |
| Charles Michaud Jr | Former Vice President, Corporate Controller and Treasurer of Homology Medicines, Inc. | 25 marca 2024 S | 927 | 0 | 0 | $0 |
| Julie Jordan | Chief Medical Officer | 3 sierpnia 2023 M | 7 496 | 0 | 0 | $0 |
| Michael Lee Blum | Chief Commercial Officer | 23 lutego 2023 A | 13 538 | 0 | 0 | $0 |
| Bradford W Smith | Chief Financial and Business Officer and Treasurer | 23 lutego 2023 A | 14 219 | 0 | 0 | $0 |
| Gabriel Cohn | Chief Medical Officer | 1 stycznia 2022 M | 2 629 | 0 | 0 | $0 |
| Diyong Xu | Dyrektor | 12 czerwca 2026 A | 625 000 | 2 | 0 | $15 000 000 |
| David S. Grayzel | Dyrektor | 12 czerwca 2026 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Dyrektor | 12 czerwca 2026 A | — | 0 | 0 | $0 |
| Isaac Manke | Dyrektor | 12 czerwca 2026 A | 53 521 | 0 | 0 | $0 |
| Arthur Tzianabos | Dyrektor | 12 czerwca 2026 A | 7 983 | 0 | 0 | $0 |
| Mark T Iwicki | Dyrektor | 12 czerwca 2026 A | — | 0 | 0 | $0 |
| Mary Thistle | Dyrektor | 12 czerwca 2026 A | — | 0 | 0 | $0 |
| Kathleen Laporte | Dyrektor | 12 czerwca 2026 A | — | 0 | 0 | $0 |
| Jeffrey V. Poulton | Dyrektor | 14 czerwca 2023 A | — | 0 | 0 | $0 |
| Alise Reicin | Dyrektor | 14 czerwca 2023 A | — | 0 | 0 | $0 |
| Matthew R Patterson | Dyrektor | 14 czerwca 2023 A | — | 0 | 0 | $0 |
| Steven Gillis | Dyrektor | 14 czerwca 2023 A | 6 068 695 | 0 | 0 | $0 |
| Kush Parmar | Dyrektor | 15 czerwca 2022 A | 181 435 | 0 | 0 | $0 |
| Richard J. Gregory | Dyrektor | 15 czerwca 2022 A | 10 806 | 0 | 0 | $0 |
| Cameron Wheeler | Dyrektor | 6 czerwca 2019 A | — | 0 | 0 | $0 |
| Mahendra Shah | Dyrektor | 2 kwietnia 2018 A | 909 742 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 4 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VII LLC, OrbiMed Genesis GP LLC ×5 zgłoszenia | 20 lipca 2026 | 13,90% | Aneks | — | SEC |
| Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, L.P., Atlas Venture Associates Opportunity II, LLC, Atlas Venture Opportunity Fund Ill, L.P., Atlas Venture Associates Opportunity III, L.P., Atlas Venture Associates Opportunity III, LLC ×2 zgłoszenia | 28 maja 2026 | 3,60% | Aneks | — | SEC |
| Acorn Bioventures, L.P., Acorn Capital Advisors, GP, LLC, Anders Hove | 4 kwietnia 2024 | — | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Management Company, L.P., James E. Flynn ×5 zgłoszenia | 1 maja 2020 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 8 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,70% | 10 132 SH | 8 sierpnia 2026 | Dziennie |
| IWC · iShares Trust | 0,03% | 29 465 SH | 8 sierpnia 2026 | Dziennie |
| AVUV · AMERICAN CENTURY ETF TRUST | 0,01% | 128 510 NS | 31 maja 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,00% | 14 652 NS | 30 kwietnia 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 314 NS | 31 maja 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 119 269 SH | 8 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 389 115 SH | 8 sierpnia 2026 | Dziennie |
| DFSV · Dimensional ETF Trust | 0,00% | 490 NS | 30 kwietnia 2026 | N-PORT |